title: Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
abstract: Small structural changes in peptides presented by major histocompatibility complex (MHC) molecules often result in large changes in immunogenicity, supporting the notion that T cell receptors are exquisitely sensitive to antigen structure. Yet there are striking examples of TCR recognition of structurally dissimilar ligands. The resulting unpredictability of how T cells will respond to different or modified antigens impacts both our understanding of the physical bases for TCR specificity as well as efforts to engineer peptides for immunomodulation. In cancer immunotherapy, epitopes and variants derived from the MART-1/Melan-A protein are widely used as clinical vaccines. Two overlapping epitopes spanning amino acid residues 26 through 35 are of particular interest: numerous clinical studies have been performed using variants of the MART-1 26-35 decamer, although only the 27-35 nonamer has been found on the surface of targeted melanoma cells. Here, we show that the 26-35 and 27-35 peptides adopt strikingly different conformations when bound to HLA-A2. Nevertheless, clonally distinct MART-1(26/27-35)-reactive T cells show broad cross-reactivity towards these ligands. Simultaneously, however, many of the cross-reactive T cells remain unable to recognize anchor-modified variants with very subtle structural differences. These dichotomous observations challenge our thinking about how structural information on unligated peptide/MHC complexes should be best used when addressing questions of TCR specificity. Our findings also indicate that caution is warranted in the design of immunotherapeutics based on the MART-1 26/27-35 epitopes, as neither cross-reactivity nor selectivity is predictable based on the analysis of the structures alone.
authors: Department of Chemistry and Biochemistry, 251 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA.
authors: Oleg Y
authors: OY
authors: Borbulevych
authors: Francis K
authors: FK
authors: Insaidoo
authors: Tiffany K
authors: TK
authors: Baxter
authors: Daniel J
authors: DJ
authors: Powell
authors: Laura A
authors: LA
authors: Johnson
authors: Nicholas P
authors: NP
authors: Restifo
authors: Brian M
authors: BM
authors: Baker
mesh_terms: D000951:Antigens, Neoplasm / Q000737:chemistry*; D019496:Cancer Vaccines / Q000276:immunology; D018360:Crystallography, X-Ray; D000939:Epitopes / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D015789:HLA-A2 Antigen / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D010455:Peptides / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D011487:Protein Conformation; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; D015789:HLA-A2 Antigen; C105787:MART-1-Melan-A(27-35) epitope; D009363:Neoplasm Proteins; D010455:Peptides; D011948:Receptors, Antigen, T-Cell
references: J Struct Biol. 1999 Apr-May;125(2-3):156-65
references: 10222271
references: J Immunol. 1999 May 1;162(9):5389-97
references: 10228016
references: Int J Cancer. 1999 Aug 27;82(5):669-77
references: 10417764
references: Immunity. 1999 Jul;11(1):45-56
references: 10435578
references: J Exp Med. 1999 Sep 6;190(5):705-15
references: 10477554
references: Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11446-51
references: 10500196
references: Nat Struct Biol. 1999 Dec;6(12):1118-21
references: 10581552
references: J Biol Chem. 1999 Dec 24;274(52):37259-64
references: 10601290
references: J Immunol. 2000 Jun 15;164(12):6398-405
references: 10843695
references: Nat Immunol. 2000 Oct;1(4):291-7
references: 11017099
references: J Immunol. 2001 Mar 1;166(5):3345-54
references: 11207290
references: Cancer Res. 2001 Mar 1;61(5):2047-54
references: 11280765
references: J Biol Chem. 2001 Jun 15;276(24):21443-9
references: 11287414
references: J Immunol. 2001 Sep 15;167(6):3276-84
references: 11544315
references: J Exp Med. 2002 Feb 18;195(4):485-94
references: 11854361
references: Immunity. 2002 Mar;16(3):345-54
references: 11911820
references: J Exp Med. 2002 Jul 15;196(2):207-16
references: 12119345
references: Nature. 2002 Aug 1;418(6897):552-6
references: 12152083
references: Immunol Rev. 2002 Oct;188:81-96
references: 12445283
references: Nat Immunol. 2003 Mar;4(3):241-7
references: 12563259
references: J Biol Chem. 2003 May 16;278(20):18581-7
references: 12604595
references: J Mol Biol. 2003 Mar 28;327(3):719-34
references: 12634064
references: Cancer Res. 2003 Apr 1;63(7):1560-7
references: 12670905
references: J Exp Med. 2004 Jan 19;199(2):271-81
references: 14734527
references: J Biol Chem. 2004 Jul 2;279(27):28197-201
references: 15084610
references: Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
references: 15299926
references: J Immunol. 2004 Nov 1;173(9):5610-6
references: 15494511
references: J Exp Med. 2004 Dec 6;200(11):1445-54
references: 15557346
references: J Exp Med. 2004 Dec 6;200(11):1455-66
references: 15583017
references: Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3429-33
references: 1565634
references: J Clin Invest. 2005 Mar;115(3):739-46
references: 15696196
references: J Immunol. 2005 Apr 15;174(8):4812-20
references: 15814707
references: J Immunol. 2005 Oct 1;175(7):4797-805
references: 16177129
references: Structure. 2006 Apr;14(4):683-93
references: 16615910
references: Science. 2006 Oct 6;314(5796):126-9
references: 16946036
references: J Mol Biol. 2006 Oct 13;363(1):228-43
references: 16962135
references: J Immunol. 2006 Nov 1;177(9):6548-59
references: 17056587
references: Nat Immunol. 2007 Mar;8(3):268-76
references: 17259989
references: EMBO J. 2007 Apr 4;26(7):1972-83
references: 17363906
references: Methods Enzymol. 1997;276:307-26
references: 27754618
references: J Exp Med. 1994 Jul 1;180(1):347-52
references: 7516411
references: J Immunol. 1995 Mar 1;154(5):2257-65
references: 7868898
references: Science. 1994 Jul 15;265(5170):398-402
references: 8023162
references: J Mol Biol. 1993 Jun 20;231(4):1049-67
references: 8515464
references: J Immunol. 1996 Sep 15;157(6):2539-48
references: 8805655
references: Science. 1996 Oct 11;274(5285):209-19
references: 8824178
references: Nature. 1996 Nov 14;384(6605):134-41
references: 8906788
references: J Immunol. 1997 Sep 1;159(5):2366-74
references: 9278327
references: J Immunol. 1998 Feb 15;160(4):1750-8
references: 9469433
references: Science. 1998 Feb 20;279(5354):1166-72
references: 9469799
references: Nat Med. 1998 Mar;4(3):321-7
references: 9500606
references: J Immunol. 1998 Apr 15;160(8):3631-6
references: 9558061
references: Immunity. 1998 Apr;8(4):403-11
references: 9586631
references: Bioinformatics. 1998;14(6):523-8
references: 9694991
references: J Immunol. 1998 Dec 15;161(12):6956-62
references: 9862730
references: J Exp Med. 1999 Jan 18;189(2):359-70
references: 9892618
references: Cancer Res. 1999 Jan 15;59(2):301-6
references: 9927036